Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import

Kylie M. Wagstaff, Stephen Headey, Sushama Telwatte, David Tyssen, Anna C. Hearps, David R. Thomas, Gilda Tachedjian, David A. Jans

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Human immunodeficiency virus (HIV) continues to be a major contributor to morbidity and mortality worldwide, particularly in developing nations where high cost and logistical issues severely limit the use of current HIV therapeutics. This, combined HIV's high propensity to develop resistance, means that new antiviral agents against novel targets are still urgently required. We previously identified novel anti-HIV agents directed against the nuclear import of the HIV integrase (IN) protein, which plays critical roles in the HIV lifecycle inside the cell nucleus, as well as in transporting the HIV preintegration complex (PIC) into the nucleus. Here we investigate the structure activity relationship of a series of these compounds for the first time, including a newly identified anti-IN compound, budesonide, showing that the extent of binding to the IN core domain correlates directly with the ability of the compound to inhibit IN nuclear transport in a permeabilised cell system. Importantly, compounds that inhibited the nuclear transport of IN were found to significantly decrease HIV viral replication, even in a dividing cell system. Significantly, budesonide or its analogue flunisolide, were able to effect a significant reduction in the presence of specific nuclear forms of the HIV DNA (2-LTR circles), suggesting that the inhibitors work though blocking IN, and potentially PIC, nuclear import. The work presented here represents a platform for further development of these specific inhibitors of HIV replication with therapeutic and prophylactic potential.

Original languageEnglish
Article numbere12953
Number of pages13
JournalCellular Microbiology
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Cite this

@article{90f833a971e64e6c8f2cb088a2a5bdfa,
title = "Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import",
abstract = "Human immunodeficiency virus (HIV) continues to be a major contributor to morbidity and mortality worldwide, particularly in developing nations where high cost and logistical issues severely limit the use of current HIV therapeutics. This, combined HIV's high propensity to develop resistance, means that new antiviral agents against novel targets are still urgently required. We previously identified novel anti-HIV agents directed against the nuclear import of the HIV integrase (IN) protein, which plays critical roles in the HIV lifecycle inside the cell nucleus, as well as in transporting the HIV preintegration complex (PIC) into the nucleus. Here we investigate the structure activity relationship of a series of these compounds for the first time, including a newly identified anti-IN compound, budesonide, showing that the extent of binding to the IN core domain correlates directly with the ability of the compound to inhibit IN nuclear transport in a permeabilised cell system. Importantly, compounds that inhibited the nuclear transport of IN were found to significantly decrease HIV viral replication, even in a dividing cell system. Significantly, budesonide or its analogue flunisolide, were able to effect a significant reduction in the presence of specific nuclear forms of the HIV DNA (2-LTR circles), suggesting that the inhibitors work though blocking IN, and potentially PIC, nuclear import. The work presented here represents a platform for further development of these specific inhibitors of HIV replication with therapeutic and prophylactic potential.",
author = "Wagstaff, {Kylie M.} and Stephen Headey and Sushama Telwatte and David Tyssen and Hearps, {Anna C.} and Thomas, {David R.} and Gilda Tachedjian and Jans, {David A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/cmi.12953",
language = "English",
journal = "Cellular Microbiology",
issn = "1462-5814",
publisher = "Wiley-Blackwell",

}

Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import. / Wagstaff, Kylie M.; Headey, Stephen; Telwatte, Sushama; Tyssen, David; Hearps, Anna C.; Thomas, David R.; Tachedjian, Gilda; Jans, David A.

In: Cellular Microbiology, 01.01.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import

AU - Wagstaff, Kylie M.

AU - Headey, Stephen

AU - Telwatte, Sushama

AU - Tyssen, David

AU - Hearps, Anna C.

AU - Thomas, David R.

AU - Tachedjian, Gilda

AU - Jans, David A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Human immunodeficiency virus (HIV) continues to be a major contributor to morbidity and mortality worldwide, particularly in developing nations where high cost and logistical issues severely limit the use of current HIV therapeutics. This, combined HIV's high propensity to develop resistance, means that new antiviral agents against novel targets are still urgently required. We previously identified novel anti-HIV agents directed against the nuclear import of the HIV integrase (IN) protein, which plays critical roles in the HIV lifecycle inside the cell nucleus, as well as in transporting the HIV preintegration complex (PIC) into the nucleus. Here we investigate the structure activity relationship of a series of these compounds for the first time, including a newly identified anti-IN compound, budesonide, showing that the extent of binding to the IN core domain correlates directly with the ability of the compound to inhibit IN nuclear transport in a permeabilised cell system. Importantly, compounds that inhibited the nuclear transport of IN were found to significantly decrease HIV viral replication, even in a dividing cell system. Significantly, budesonide or its analogue flunisolide, were able to effect a significant reduction in the presence of specific nuclear forms of the HIV DNA (2-LTR circles), suggesting that the inhibitors work though blocking IN, and potentially PIC, nuclear import. The work presented here represents a platform for further development of these specific inhibitors of HIV replication with therapeutic and prophylactic potential.

AB - Human immunodeficiency virus (HIV) continues to be a major contributor to morbidity and mortality worldwide, particularly in developing nations where high cost and logistical issues severely limit the use of current HIV therapeutics. This, combined HIV's high propensity to develop resistance, means that new antiviral agents against novel targets are still urgently required. We previously identified novel anti-HIV agents directed against the nuclear import of the HIV integrase (IN) protein, which plays critical roles in the HIV lifecycle inside the cell nucleus, as well as in transporting the HIV preintegration complex (PIC) into the nucleus. Here we investigate the structure activity relationship of a series of these compounds for the first time, including a newly identified anti-IN compound, budesonide, showing that the extent of binding to the IN core domain correlates directly with the ability of the compound to inhibit IN nuclear transport in a permeabilised cell system. Importantly, compounds that inhibited the nuclear transport of IN were found to significantly decrease HIV viral replication, even in a dividing cell system. Significantly, budesonide or its analogue flunisolide, were able to effect a significant reduction in the presence of specific nuclear forms of the HIV DNA (2-LTR circles), suggesting that the inhibitors work though blocking IN, and potentially PIC, nuclear import. The work presented here represents a platform for further development of these specific inhibitors of HIV replication with therapeutic and prophylactic potential.

UR - http://www.scopus.com/inward/record.url?scp=85053924021&partnerID=8YFLogxK

U2 - 10.1111/cmi.12953

DO - 10.1111/cmi.12953

M3 - Article

JO - Cellular Microbiology

JF - Cellular Microbiology

SN - 1462-5814

M1 - e12953

ER -